Keywords: Navidea Biopharma, Lymphoseek, USA, FDA, Manufacturing issues, Diagnostic aid

FDA delays approval of Navidea's Lymphoseek

Article | 11 September 2012

Print This

US biotech company Navidea Biopharmaceuticals (NYSE: NAVB) says it has received a Complete Response Letter (CRL) from the US Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in